MolNFT v1 · #30750 · protein
Crystal structure of human TASPASE1 (acivated form)
2A8J · Threonine aspartase 1: “Crystal structure of human TASPASE1 (acivated form)”. X-ray diffraction, 1 ligand (CL), 9 pockets (best druggability 0.62). MolNFT v1 #30750 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 2A8J
- Type
- protein
- Length
- 623 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Threonine aspartase 1
- EC
- 3.4.25.-
- UniProt
- Q9H6P5
- Ligands
- CL
- Pockets
- 9 · best druggability 0.62
Structure
x-ray diffraction · 2 distinct chains · 29% helix, 31% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Threonine aspartase 1 (EC 3.4.25.-) | protein | 310 | 30% helix, 31% strand | Q9H6P5 |
| B | Threonine aspartase 1 (EC 3.4.25.-) | protein | 313 | 29% helix, 30% strand | Q9H6P5 |
Ligands and binding sites
- CL · Chloride ion · ion · 2 copies · chains A, B
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
9 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 352 | 0.62 | 0.78 | 44 | CL |
| 2 | 332 | 0.61 | 0.78 | 50 | CL |
| 3 | 191 | 0.56 | 0.80 | 24 | empty |
| 4 | 85 | 0.50 | 0.84 | 23 | empty |
| 5 | 78 | 0.47 | 0.83 | 24 | empty |
Interfaces
1 interface between chains.
- A–B · 2057 Ų buried · 30 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q9H6P5
- Elsewhere: RCSB PDB 2A8J · PDBe 2A8J · UniProt Q9H6P5
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.